CN1172933C - Prepn of matrine, oxymatrine and sophoxidine from flavescent sophora root - Google Patents

Prepn of matrine, oxymatrine and sophoxidine from flavescent sophora root Download PDF

Info

Publication number
CN1172933C
CN1172933C CNB031080634A CN03108063A CN1172933C CN 1172933 C CN1172933 C CN 1172933C CN B031080634 A CNB031080634 A CN B031080634A CN 03108063 A CN03108063 A CN 03108063A CN 1172933 C CN1172933 C CN 1172933C
Authority
CN
China
Prior art keywords
matrine
sophorine
oxymatyine
kuh
seng
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB031080634A
Other languages
Chinese (zh)
Other versions
CN1453276A (en
Inventor
王答祺
李静
王新莉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNB031080634A priority Critical patent/CN1172933C/en
Publication of CN1453276A publication Critical patent/CN1453276A/en
Application granted granted Critical
Publication of CN1172933C publication Critical patent/CN1172933C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to a technology for producing matrine, oxymatrine and sophoxidine from kuh-seng, which is characterized in that matrine crude products and sophoridine crude products are respectively formed by that kuh-seng is carried out on extraction, concentration, alkalization, recovery, solvent extraction, acid back extraction, deposition and separation after dried and crushed, and the matrine crude products and sophoridine crude products are recrystalled and dried to obtain matrine products and sophoridine products. Oxymatrine products can be obtained by that the matrine is carried out on oxidization, hydration, pressure reducing, distillation, crystallization, filtering, recrystallization and drying. The three types of products are medical manufacturing raw materials which can be used for preparing medicine for treating the disease, such as hepatitis b, hepatitis c, white cell deterioration, heart rate aberration, cancer, etc. The present invention has the advantages of simple productive process, low cost and high purity degree, and is suitable for large scale commercial production.

Description

A kind of production technique that from kuh-seng, prepares matrine, Oxymatyine and sophorine
Technical field
The present invention relates to a kind of from kuh-seng preparation can be used for matrine, the Oxymatyine of medical material, the production technique of sophorine.
Background technology
Kuh-seng is a kind of herbal medicine commonly used, in the successive dynasties book on Chinese herbal medicine works record is arranged more, is the dry root of cassia leguminous plant kuh-seng (Sophora flavscens Alt.), has effects such as heat-clearing, dehumidifying, desinsection, diuresis; China extensively distributes, aboundresources, contained alkaloid composition is considered to main biological activity wherein in the kuh-seng, at present from kuh-seng isolation identification 17 kinds of alkaloid compositions, be mainly: sophocarpine (Sophocarpine), matrine (matrine), sophorine (sophoridine), Oxymatyine (oxymatrine), Sophocarpidin (oxysophcarpine), this in five alkaloid account for more than 90% of total alkaloids, pharmacological evaluation and clinical application prove, kuh-seng and preparation thereof can be treated acute bacillary dysentery, trichomoniasis, bronchial asthma and asthmatic bronchitis, oedema and ascites, the treatment tetter, heart disorder and viral myocarditis, hypnosis and treatment mania, particularly Oxymatyine can be treated tumor radiotherapy, the white corpuscle that chemotherapy causes lowly reaches the leukopenia that other reason causes, the chronic viral hepatitis B and third liver are being applied to require Oxymatyine bulk drug purity more than 98% when clinical; Sophorine has antitumour activity to multiple animal-transplanted tumor, clinical suede cancer malignant mole, lung cancer, digestive tract cancer antitumous effect obviously stablized, and be a kind of of great value PTS.
From Herba Sophorae alopecuroidis, extract matrine at present mostly, Oxymatyine or sophorine, from kuh-seng, extract matrine, the bibliographical information of Oxymatyine or sophorine is few, and all be from kuh-seng, once can only extract a kind of alkaloid, CN1073681A for example, open day is on June 30th, 1993, reported the method for from kuh-seng, extracting matrine with the freezing vacuum method, from kuh-seng, once extract matrine, the bibliographical information of Oxymatyine and sophorine is not found so far, and traditional preparation technology, the program complexity, the cost height, be difficult to form commercial scale production, can not reach the purity more than 98%, hinder matrine greatly, Oxymatyine, sophorine is in pharmacy and application clinically.
Summary of the invention
The purpose of this invention is to provide a kind of novel process that from kuh-seng, prepares matrine, Oxymatyine, sophorine simultaneously, and technology is simple, cost is low, purification degree is high.
The present invention is achieved by the following scheme:
Extract total alkaloids is according to very easily water-soluble principle behind contained alkaloid in the plant and the sour salify from kuh-seng, the kuh-seng of pulverizing is wetting with dilute sulphuric acid, make alkaloid salify wherein, extract with the alkaloid of enough water after again salify, water is evaporated, make total alkaloids become paste; Under unbound state, be soluble in organic solvent according to total alkaloids again, be insoluble in the principle of water, total alkaloids is alkalized with sodium hydroxide, make alkaloid become unbound state, wherein Oxymatyine and Sophocarpidin are reduced into matrine and sophocarpine, pass through organic solvent extraction, make alkaloid transfer to organic phase, strip with acid then, make alkaloid change aqueous phase over to, and exist with the form of salt from organic phase; When dissociating alkaloid with alkali, matrine at first crystallizes out; Mother liquor also can obtain matrine, sophorine through separating; Through recrystallization, get matrine and sophorine product; Matrine can generate Oxymatyine after peroxidation.Therefore excessive matrine and hydrogen peroxide carries out oxidizing reaction, can obtain Oxymatyine, and make hydrogen peroxide all change into water, do not bring other impurity in the material into; Concentrating under reduced pressure is removed most of water again, and crystallization, recrystallization obtain the Oxymatyine product.
The concrete production method of the present invention is as follows:
1. with the kuh-seng drying and crushing, granularity is the 10-60 order, uses 0.5%H 2SO 4Wetting, place more than 2 hours.With the wetting raw material stainless steel multi-function extractor of packing into, below 80 ℃, with water extraction 3 times, 3 water consumptions amount to 10 times of kuh-seng raw material, united extraction liquid, and the material slag discards;
2. extracting solution is condensed into the medicinal extract shape with double-effect evaporator, proportion 〉=1.2;
3. medicinal extract alkalizes to PH 〉=9 with alkali lye, adds reductive agent again, check that with thin-layer chromatography wherein the spot of Oxymatyine and Sophocarpidin disappears till;
4. be taken to till lifeless matter alkali detects in the medicinal extract with organic solvent extracting through above-mentioned 3 medicinal extract of handling, water layer discarded, organic solvent extraction liquid is stripped with acid solution, till organic layer lifeless matter alkali reaction, make alkaloid all change water layer over to, isolate water layer, organic solvent can be used repeatedly;
5. contain alkaloidal water layer and alkalize to PH=10-11 with alkali lye, the solution layering, lower layer of water discards, and upper strata total alkaloids cream is placed, and crystallization goes out matrine, filters, and gets the matrine crude product;
6. mother liquor also can get matrine crude product and sophorine crude product through anti-distributions chromatographic separation more than 7 grades, merges 5,6 gained matrine crude products, and recrystallization gets the matrine product repeatedly, and the sophorine crude product gets the sophorine product through recrystallization;
7. above-mentioned 6 gained matrine products and hydrogen peroxide are added reactor, dissolve under 50 ℃, 60 ℃ are reacted complete to hydrogen peroxide consumption, concentration of reaction solution below 80 ℃ is to there being crystalline particle to occur, add the acetone crystallization, use acetone recrystallization again, get the Oxymatyine product.
Wherein reductive agent is a Sodium Pyrosulfite; Alkali lye is sodium hydroxide, potassium hydroxide, ammonium hydroxide, yellow soda ash; Organic solvent is a kind of in trichloromethane, methylene dichloride, the benzene,toluene,xylene; The used acid of acid solution reextraction is sulfuric acid or hydrochloric acid.
The concrete grammar that thin-layer chromatography of the present invention is measured is:
Get thin-layer chromatography silica gel special G, be modulated into the emulsifiable paste shape with 2%NaOH solution, make thin layer plate,, the sample and the reference substance thereof of sophorine, Oxymatyine and matrine are put in the thin layer plate bottom 100 ℃ of activation 1 hour, with chloroform: acetone: methyl alcohol=3: 2: 1 is developping agent, carry out thin-layer chromatography, with the Dragendorff's reagent colour developing of improvement, the Rf value is respectively sophorine 0.67 again, Oxymatyine 0.29, matrine 0.79.
Be not difficult to find out that from above content advantage of the present invention is:
1 once feeds intake can get three kinds of products simultaneously, greatly reduces cost
2 technologies are simple, are fit to suitability for industrialized production
3 quality are good, inclusion-free, purity height, and three kinds of products all reach more than 98%
For advantage of the present invention is described better, be illustrated by following experiment:
Experiment one
Get 0.5 kilogram of gained Oxymatyine of the present invention, test for No. 001 by (1998) traditional Chinese medicines marking-up, the gained result is as follows;
Interventions Requested standard code assay
[proterties] becomes white or off-white color crystalline powder white crystalline powder
[discriminating] (1) should be the positive reaction positive reaction
(2) should be the positive reaction positive reaction
[inspection]
Moisture must not cross 8.5% 7.5%
It is 0.4% up to specification that residue on ignition must not be crossed
It is 10/10000ths up to specification that heavy metal must not be crossed
Related substance % should be up to specification
[assay] must not be less than 98.0% 99.5% conclusions by dry product: this product is checked above-mentioned project No. 001 by (1998) traditional Chinese medicines marking-up, and the result is up to specification.
Experiment two
Get 0.8 kilogram of gained matrine of the present invention, test by national drug standards WS-10001-(HD-0047) 2002, the gained result is as follows:
Interventions Requested standard code assay
[proterties] this product is white, needle-shaped crystals or white, needle-shaped crystals powder
Crystalline powder, odorless, bitter odorless, bitter
Specific optical rotation (25 ℃+) 31.0-36.0 34.3
[discriminating] (1), (2) are positive reaction (1), (2) positive reaction
[inspection]
Basicity (PH) 9.5-10.5 10.4
The clarity of solution and color are up to specification
Oxide compound %≤0.01 is up to specification
Weight loss on drying %≤1.0 are up to specification
Residue on ignition %≤0.1 is up to specification
Heavy metal≤20ppm is up to specification
Related substance %≤2.0 0.6
[assay] is by dry product 98.0%-101.0% 99.5% conclusion: this product is tested by national drug standards WS-10001-(HD-0047) 2002, and is up to specification.
Experiment three
Get 0.3 kilogram of method with reference to matrine of gained sophorine of the present invention (still can't calibrate standard at present) and test, the result is as follows;
The Interventions Requested assay
[proterties] white, needle-shaped crystals
[discriminating] (1), (2) positive reaction
[inspection]
Weight loss on drying % 0.8
Residue on ignition % 0.01
Heavy metal 10ppm
Related substance % 0.5
[assay] pressed dry product and calculated 98.8%
Conclusion: up to specification.
Description of drawings
Fig. 1 is the process flow sheet of preparation matrine, sophorine
Fig. 2 is the process flow sheet of preparation Oxymatyine
Embodiment:
Select the northwest to produce the high-quality kuh-seng, drying is pulverized 40 orders, gets 200 kilograms in kuh-seng powder, uses 0.5%H 2SO 4Solution 100L is wetting, places more than 2 hours, in the 2000L stainless steel multi-function extractor of packing into, adds 800L water for the first time, heats 75 ± 5 ℃, keeps this temperature, forces water cycle 2 hours, leaches solution; In multi-function extractor, add 600L water for the second time, heat 75 ± 5 ℃, keep this temperature, force water cycle 2 hours, leach solution; In multi-function extractor, add 500L water for the third time again, heat 75 ± 5 ℃, keep this temperature, force water cycle 2 hours, leach solution; Merge No. three times extracting solution, the leaching clear liquid uses double-effect evaporator at 80 ℃, and the following vacuum condition of-0.08MPa concentrates down, and evaporation removes and anhydrates, and makes it into the medicinal extract shape, and proportion 〉=1.2 get 95 kilograms of medicinal extract, and yield is 47.5%; Medicinal extract adds flaky sodium hydrate and transfers to PH 〉=9, adds the reductive agent Sodium Pyrosulfite again thin-layer chromatography is checked in the medicinal extract till the non-oxidation matrine and Sophocarpidin spot; Medicinal extract is with dichloromethane extraction 6 times, and each 150L is till the lifeless matter alkali reaction; Dichloromethane extraction liquid is stripped till the lifeless matter alkali reaction with 8% hydrochloric acid soln; Make alkaloid all change water layer over to, isolate water layer, organic solvent can be used repeatedly; Contain alkaloidal water layer and alkalize to PH=10-11 with sodium hydroxide, the solution layering, lower layer of water discards, and the upper strata is a total alkaloids cream; Total alkaloids cream is placed and to be spent the night, i.e. crystallization goes out matrine, filter the matrine crude product; Mother liquor also can obtain matrine crude product and sophorine crude product through anti-distributions chromatographic separation more than 7 grades, merges gained matrine crude product twice, through recrystallization repeatedly, 1.42 kilograms of pure product of matrine, content 98.3% (by dry product), water content 19.7%.
The sophorine crude product gets 0.2 kilogram of sophorine product, content 98.5% (by dry product), water content 1.2% through recrystallization.
With 1.4 kilograms of the pure product of above-mentioned gained matrine, add hydrogen peroxide 600ml, after 50 ℃ of heating for dissolving of water-bath, 60 ℃ of reacting by heating of water-bath stir simultaneously, per 2 hours inspection content of hydrogen peroxide, reaction terminating when no hydrogen peroxide detects in solution; Using the vacuum decompression thickener, is thermal source with 80 ℃ of water, under the following vacuum condition of-0.08MPa, reaction solution has been concentrated into crystallization has separated out, and adds acetone 1500ml, stirs, and is placed to room temperature, and crystallization is separated out, and leaches crystallization, gets the Oxymatyine crude product; Use acetone recrystallization again, filter, vacuum-drying gets 0.95 kilogram of Oxymatyine product, content 98.5% (by dry product), and water content 6.5%, total yield is 0.475%.

Claims (5)

1. production technique for preparing matrine, Oxymatyine, sophorine from kuh-seng is characterized in that may further comprise the steps:
(1) with the kuh-seng drying and crushing, granularity is the 10-50 order, uses 0.5%H 2SO 4Wetting, place more than 2 hours, wetting raw material is packed in the stainless steel multi-function extractor, below 80 ℃, with water extraction 3 times, 3 water consumptions amount to 10 times of kuh-seng raw material, united extraction liquid, the material slag discards;
(2) extracting solution is condensed into the medicinal extract shape with double-effect evaporator, proportion 〉=1.2;
(3) medicinal extract alkalizes to PH 〉=9 with alkali lye, adds Sodium Pyrosulfite again, check that with thin-layer chromatography wherein the spot of Oxymatyine and Sophocarpidin disappears till;
(4) medicinal extract of handling through above-mentioned (3) is taken to till lifeless matter alkali detects in the medicinal extract with organic solvent extracting, water layer discarded, and organic solvent extraction liquid is stripped with acid solution, till organic layer lifeless matter alkali reaction, make alkaloid all change water layer over to, isolate water layer, organic solvent can be used repeatedly;
(5) contain alkaloidal water layer and alkalize to PH=10-11 with alkali lye, the solution layering, lower layer of water discards, and upper strata total alkaloids cream is placed, and crystallization goes out matrine, filters, and gets the matrine crude product;
(6) mother liquor also can get matrine crude product and sophorine crude product through anti-distributions chromatographic separation more than 7 grades, merges (5), (6) gained matrine crude product, and periodic crystallisation gets the matrine product, and recrystallization sophorine crude product gets the sophorine product;
(7) above-mentioned (6) gained matrine product and hydrogen peroxide are added reactor, dissolve under 50 ℃, 60 ℃ are reacted complete to hydrogen peroxide consumption, concentration of reaction solution below 80 ℃ is to there being crystalline particle to occur, add the acetone crystallization, use acetone recrystallization again, get the Oxymatyine product.
2. production technique according to claim 1 is characterized in that used alkali lye is sodium hydroxide, potassium hydroxide, ammonium hydroxide, yellow soda ash.
3. production technique according to claim 1, it is characterized in that used organic solvent is wherein a kind of in trichloromethane, methylene dichloride, the benzene,toluene,xylene.
4. production technique according to claim 1 is characterized in that the used acid of acid solution reextraction is sulfuric acid or hydrochloric acid.
5. production technique according to claim 1 is characterized in that the concrete grammar that thin-layer chromatography is measured is:
Get thin-layer chromatography silica gel special G, be modulated into the emulsifiable paste shape with 2%NaOH solution, make thin layer plate,, the sample and the reference substance thereof of sophorine, Oxymatyine and matrine are put in the thin layer plate bottom 100 ℃ of activation 1 hour, with chloroform: acetone: methyl alcohol=3: 2: 1 is developping agent, carry out thin-layer chromatography, with the Dragendorff's reagent colour developing of improvement, the Rf value is respectively sophorine 0.67 again, Oxymatyine 0.29, matrine 0.79.
CNB031080634A 2003-05-22 2003-05-22 Prepn of matrine, oxymatrine and sophoxidine from flavescent sophora root Expired - Fee Related CN1172933C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB031080634A CN1172933C (en) 2003-05-22 2003-05-22 Prepn of matrine, oxymatrine and sophoxidine from flavescent sophora root

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB031080634A CN1172933C (en) 2003-05-22 2003-05-22 Prepn of matrine, oxymatrine and sophoxidine from flavescent sophora root

Publications (2)

Publication Number Publication Date
CN1453276A CN1453276A (en) 2003-11-05
CN1172933C true CN1172933C (en) 2004-10-27

Family

ID=29259898

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB031080634A Expired - Fee Related CN1172933C (en) 2003-05-22 2003-05-22 Prepn of matrine, oxymatrine and sophoxidine from flavescent sophora root

Country Status (1)

Country Link
CN (1) CN1172933C (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100528855C (en) * 2005-12-27 2009-08-19 中国科学院山西煤炭化学研究所 Process for producing kuh-seng total flavone and flavone salt by kuh-seng
CN100528856C (en) * 2005-12-27 2009-08-19 中国科学院山西煤炭化学研究所 Process for producing kuh-seng total flavone and flavone salt
CN100439364C (en) * 2005-12-27 2008-12-03 中国科学院山西煤炭化学研究所 Process for producing high purity matrine oxide
CN100439363C (en) * 2005-12-27 2008-12-03 中国科学院山西煤炭化学研究所 Process for producing high purity matrine oxide by kuh-seng
CN101336958B (en) * 2008-02-15 2013-01-16 上海海天医药科技开发有限公司 Use of alkaloids extracted from sophora flavescens in preparing medicine for treating diseased induced by mycoplasma, chlamydia and fungus
CN103503890A (en) * 2012-06-29 2014-01-15 江苏天晟药业有限公司 Biological pesticide emulsion and preparation method thereof
CN104498558B (en) * 2015-01-15 2017-10-10 遵义医学院 A kind of method that utilization microorganism prepares Sophoridine
CN104531591B (en) * 2015-01-15 2017-03-08 遵义医学院 One plant has the bacterial strain catalyzing and synthesizing sophoridine
CN104630304B (en) * 2015-02-04 2017-10-17 遵义医学院 A kind of method that utilization microorganism prepares sophoridine oxide
CN106188056B (en) * 2016-07-19 2018-07-06 广州中大南沙科技创新产业园有限公司 A kind of extracting method of matrine
CN106075521B (en) 2016-08-10 2017-08-11 王婧宁 Air purifying preparation composition
CN108690025A (en) * 2017-04-12 2018-10-23 山西纳安生物科技有限公司 Utilize the method for active ingredient in acidic oxidation and alkaline reduction electric potential water extraction kuh-seng
CN108558880A (en) * 2018-05-14 2018-09-21 宁县恒瑞康生物科技有限公司 A kind of production method for extracting matrine from kuh-seng
CN109575009B (en) * 2018-12-26 2020-04-14 成都普思生物科技股份有限公司 17-hydroxy new matrine and its extraction method and application
CN114591329B (en) * 2022-03-03 2023-07-28 西安岳达生物科技股份有限公司 Method for interconverting kuh-seng functional components
CN115624577A (en) * 2022-09-09 2023-01-20 厦门海关技术中心 Sophora flavescens alkaloids, extraction and purification method thereof, and method for detecting Sophora flavescens alkaloids

Also Published As

Publication number Publication date
CN1453276A (en) 2003-11-05

Similar Documents

Publication Publication Date Title
CN1172933C (en) Prepn of matrine, oxymatrine and sophoxidine from flavescent sophora root
CN112979733B (en) Anti-hepatitis B virus compound and preparation method and application thereof
CN101255180B (en) Diphenyl ethylene glycosides derivatives
CN101288695B (en) Preparation technique of alkaloids from Stephania tetrandra
CN103540640A (en) Preparation method of timosaponin A III
CN102174009A (en) Method for preparing indigo and indirubin from dyers woad leaf
CN111747881B (en) Two isopentenyl substituted indole alkaloids with alpha-glucosidase inhibition effect, and preparation method and application thereof
CN107043362B (en) A kind of intermediate of epirubicin hydrochloride compounds Ⅳ
CN107445952A (en) A kind of with extracting Glan new and coptisine methods and applications
CN101941908A (en) Method for preparing and partially-synthesizing chlorogenic acid from processing residual liquid of aqua lonicerae foliae
CN109400566B (en) Method for extracting and separating high-purity amentoflavone from Selaginella plant
CN111233689A (en) 13Purification method and preparation method of C-methaoxetine
CN115260210A (en) Cepharanthine crystal form and preparation method thereof
CN102127127A (en) Kanamycin extracting process
CN113956293A (en) Propofol fumarate tenofovir impurity TA-Q5 salt and preparation method and application thereof
CN101544575B (en) Method for preparing natural 4-hydroxy-isoleucine
CN107382875A (en) A kind of synthetic method of rosuvastain calcium chiral isomer impurity
CN112521440B (en) Method for purifying cyclochrysine D
CN113354581A (en) Preparation method and application of chiral chloroquine and phosphate thereof
CN110872307B (en) Thiazole medicine molecule used in hospital and gynecology and preparation method and application thereof
CN107286143B (en) Canagliflozin medicine impurity and preparation method and application thereof
CN109096273A (en) The method for separating and preparing of mezlocillin sodium impurity C, D and F
EP2007766A1 (en) Narcotine purification process
CN115703740B (en) Preparation method of bulleyaconitine A
CN113461704B (en) Monoterpene coumarin compound, preparation method and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee